Skip to main content

Table 1 Potential therapeutic/preventative strategies targeting cardiac events in patients with community-acquired pneumonia

From: Prevalence, pathogenesis, therapy, and prevention of cardiovascular events in patients with community-acquired pneumonia

• Anti-platelet agents  
 o inhibitors of production of thromboxane A2  
 o antagonists of thromboxane A2 receptors  
 o antagonists of ADP-activated P2Y12 receptors  
 o antagonists of thrombin-activated proteinase-activated receptor 1  
 o GPIIb/IIIa inhibitors  
• Agents targeting pneumolysin  
 o macrolides  
 o statins  
 o cholesterol-rich liposomes  
• Immunisation  
 o PCV 13 with or without immunogenic pneumolysoid